Botulinum toxin for achalasia: Results of a controlled trial with a follow-up of twelve months

Fiorini, A; Corti, RE; Valero, JL; Bai, JC; Boerr, Luis A.

doi:10.1016/s0016-5107(96)80180-5

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the first encouraging report of a pilot trial in humans, the results were confirmed by the same authors in a double‐blind, placebo‐controlled study of 21 achalasic patients treated with Botx 43 , . 44 Since then, several studies have appeared in the literature; most of them, however, have been reported only in abstract form, as shown in Table 4 45 –61 . Overall, these studies in more than 450 patients showed an average decrease in LOS pressure of 32% (range 5–58%) and good clinical improvement at 1‐month follow‐up in 77% of cases (range 50–100%).…”

Section: Methodsmentioning

confidence: 99%

Review article: pharmacological options in achalasia

Bassotti

Annese

1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Achalasia is a common primary oesophageal motor disorder. Treatment has been based traditionally on a surgical approach; however, there is new evidence that some medical strategies may be of benefit. The purpose of the present article was to review the current medical management of achalasia. A Medline search identified original articles and reviews published in the English‐language literature between 1966 and 1998. This search has revealed that the pharmacological treatment of achalasia is limited to some subgroups of patients (for example, early stages of the disease and elderly patients), and that nitrates, nifedipine, and botulinum toxin are the best studied and most effective compounds.

show abstract